Clinical Trial Update: Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Rituxan (rituximab) and chemotherapy followed by Zevalin (ibritumomab tiuxetan) for low-grade follicular non-Hodgkin lymphoma has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Non-Hodgkins Lymphoma | Phase 2 | Status: COMPLETED